Erik Ensrud is a Neurology physician. OpenAlex indexes 54 publications with 1,173 citations (h-index 12); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
300 Pasteur Dr
Stanford, CA 943052200
Telephone
650-723-4000Provider last certified this registry record 17 Mar 2026.
Clinical trials
- Noninvasive Assessment of Neuromuscular Disease Using Electrical Impedance Myography
Sponsor: Skulpt, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ARGENX US, INC.Program year20232 payments
- ARGENX US, INC.Program year20227 payments
- Biohaven Pharmaceuticals, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
62.6%Other nervous system drugs21.3%Radicava Ors100%Part D<11 patientsCholinesterase Inhibitor13.9%Pyridostigmine Bromide100%Part D<11 patients+ 3 more classes in this area
Metabolism & gastrointestinal
16.1%Corticosteroid10.4%Prednisone100%Part D<11 patientsH2 blocker5.7%Famotidine100%Part D<11 patientsBlood & clotting
10.9%Salt solutions10.9%Sodium Chloride100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Acquired adermatoglyphia associated with sporadic inclusion body myositis
RRNMF Neuromuscular Journal
2025 - COVID-19: a modern trigger for Guillain-Barre syndrome, myasthenia gravis, and small fiber neuropathy
Frontiers in Neuroscience
2023 - How Do Standing Neutral, Supine Lateral, Standing Flexion, and Standing Extension Radiographs Compare in Detecting the Presence and Magnitude of Stable and Dynamic Spondylolisthesis?
Clinical Orthopaedics and Related Research
2023
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Bruce Miller, MD
University of California, San Francisco (UCSF)
Brett Kissela, MD
Medical College of Wisconsin
Bradley Boeve, MD
Mayo Clinic
Richard Lipton, MD
Albert Einstein College of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”